In vivo KCNQ1-suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Private company. Main funding source(s): Pfizer BACKGROUND: Type 1 long QT syndrome (LQT1) is a genetic channelopathy characterized by both haploinsufficient and dominant-negative loss-of-function pathogenic variants in the KCNQ1-encoded Kv7.1 K+ ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Giammarino, L, Nimani, S, Bains, S, Alerni, N, Tester, D J, Christoforou, N, Louradour, J, Jurgensen, J, Barry, M A, Koren, G, Zehender, M, Brunner, M, Brooks, G, Ackerman, M J, Odening, K E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
41.4.5 - Ion Channels, Electrophysiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206659/
http://dx.doi.org/10.1093/europace/euad122.594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206659/
http://dx.doi.org/10.1093/europace/euad122.594

Ejemplares similares